Molecular and cellular mediators of innate and adaptive immune responses play a major role in both the initiation and the progression of stroke. They also participate in the induction of tolerance to ischemia by sublethal preconditioning stresses. We have investigated such mediators in the three abovementoned facets of stroke. Inhibition of tumor necrosis factor(TNF) with TNF-binding protein reduces brain infarct volume in middle cerebral artery occlusion (MCAO) models in the rat and mouse. In addition, TNF-binding protein attenuates the progressive impairment of microvascular perfusion that occurs during the early hours of focal brain ischemia. These findings implicate TNF as a mediator of progressive brain damage during acute stroke. Lipopolysaccharide (LPS) pretreatment has been demonstrated to induce tolerance to focal brain ischemia in the MCAO model in spontaneously hypertensive rats (SHR). TNF binding protein blocks this tolerance implicating TNF as a mediator of this state of preserved homeostasis under stress. This form of tolerance also reduces the degree of microcirculatory perfusion impairment in brain. Preconditioning with TNF by intracisternal injection of TNF induces tolerance to ischemia in the Balb/C mouse. In vitro models comprising cellular elements of brain have been established in order to examine the mechanisms involved in the observed in vivo tolerance to ischemia of the brain pretreated either by TNF or by oxygen/glucose deprivation (OGD). Pretreatment of primary neuronal cultures with short hypoxia (15 minutes) 24 hours prior to 60 minutes of hypoxia, protected neurons against hypoxia (number of dead cells was 9.4% versus 35% in non-pretreated cultures). Pretreatment with TNF (50 ng/ml) also protected cortical neurons against 60 minutes of hypoxia. TNF-preconditioning can induce tolerance to subsequent OGD in brain microvessel endothelial cells, astrocytes and cortical neurons. In cortical astrocytes from 2-3 day old Sprague-Dawley rats, preconditioning with TNF-alpha to produce tolerance does not inhibit I-kappaB proteolysis, nuclear translocation of NF-kappaB or binding of the p65 subunit of NFkB to its consensus site on DNA. It does, however, prevent p65 phosphorylation and consequently disrupts the association of the coactivator protein, p300/CBP, with that subunit. The result is that expression of proinflammatory genes such as ICAM-1 is inhibited, but expression of cytoprotective genes such as manganese superoxide dismutase continues unabated. In bedside to bench studies, mouse anti-rat ICAM-1 antibody induced an inflammatory state in preclinical models of ischemic stroke that included activation of complement (C3a desArginine), granulocytes (CD11b up-regulation), and endothelium (E- and P-selectin expression). Serial administration of the antibody sensitized rats to produce anti-mouse antibodies and augmented infarct size in a focal brain ischemia model. Similar responses to the mouse anti-human ICAM-1 monoclonal antibody (a non-humanized antibody), Enlimomab, may have contributed to the adverse outcomes of the Enlimomab acute stroke trial. A form of immunological tolerization, mucosal tolerance, has been shown to target regulatory T cells to activating endothelium and to prevent strokes. Mucosal tolerance to E-selectin, which is an adhesion molecule that only becomes expressed on endothelium when a vessel segment becomes activated, has been shown to profoundly reduce ischemic strokes and to eliminate hemorrhages that otherwise occur spontaneously in spontaneously hypertensive and genetically stroke-prone rats (SHR-SP). E-selectin tolerization also can reduce infarct size after MCAO in SHR-SP and this cytoprotection can be adoptively transferred by splenocytes from tolerized animals indicating that the protection is cell-mediated. This novel approach to stroke prevention is being translated into clinical trials involving the secondary preventon of stroke and Binswanger Disease. GMP recombinant murine and human E-selectin has been produced with a baculovirus expression vector platform and is being used in preclinical toxicology and immunotoxicology studies in mice and non-human primates as a prerequisite for obtaining an IND. Additional studies have shown that E-selectin tolerization markedly inhibits white matter damage in models of vascular dementia and experimental autoimmune encephalomyelitis. E-selectin tolerization also suppresses delayed vasospasm in a subarachnoid hemorrhage model. A bedside to bench proposal has supported the study of E-selectin tolerization in a model of atherosclerosis where the tolerization suppresses lipid deposition in the aortic arches of APOE null mice on a Western diet. Current work follows a critical path to Phase I testing. We are currently working on a go-no go test in which we need to observe suppression of delayed type sensitivity in primates in order to proceed. If successful, we plan to file an IND and initiate a Phase I clinical trial in Binswanger Disease, an Orphan Disease, with Dr. Gary Rosenberg at the University of New Mexico. If the initial trial raises no flags, we will continue with the Binswanger studies at U. New Mexico and will also initiate clinical trials of the prevention of secondary stroke at the NINDS. Our early and current work has demonstrated that the relationship between risk factors and stroke involves a chronic, subtle, immune dysregulation. Accordingly, we are examining additional ways to immunomodulate activating blood vessels in order to reduce stroke damage.A promising current approach involves injection of a suppressive telomeric sequence oligodeoxynucleotide, TTAGGG, that has demonstrated cytoprotective properties in models of brain ischemia.

Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
2015
Total Cost
Indirect Cost
City
State
Country
Zip Code
Bogoslovsky, Tanya; Bernstock, Joshua D; Bull, Greg et al. (2018) Development of a systems-based in situ multiplex biomarker screening approach for the assessment of immunopathology and neural tissue plasticity in male rats after traumatic brain injury. J Neurosci Res 96:487-500
Bernstock, Joshua D; Ye, Daniel G; Lee, Yang-Ja et al. (2018) Drugging SUMOylation for neuroprotection and oncotherapy. Neural Regen Res 13:415-416
Bernstock, Joshua D; Ye, Daniel; Smith, Jayden A et al. (2018) Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMO-specific protease (SENP)2. FASEB J 32:1677-1691
Bernstock, Joshua D; Peruzzotti-Jametti, Luca; Ye, Daniel et al. (2017) Neural stem cell transplantation in ischemic stroke: A role for preconditioning and cellular engineering. J Cereb Blood Flow Metab 37:2314-2319
Bernstock, Joshua D; Lee, Yang-ja; Peruzzotti-Jametti, Luca et al. (2016) A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. J Cereb Blood Flow Metab 36:426-41
Lee, Yang-Ja; Bernstock, Joshua D; Nagaraja, Nandakumar et al. (2016) Global SUMOylation facilitates the multimodal neuroprotection afforded by quercetin against the deleterious effects of oxygen/glucose deprivation and the restoration of oxygen/glucose. J Neurochem 138:101-16
Zhao, Jing; Mou, Yongshan; Bernstock, Joshua D et al. (2015) Synthetic Oligodeoxynucleotides Containing Multiple Telemeric TTAGGG Motifs Suppress Inflammasome Activity in Macrophages Subjected to Oxygen and Glucose Deprivation and Reduce Ischemic Brain Injury in Stroke-Prone Spontaneously Hypertensive Rats. PLoS One 10:e0140772
Miyake, Shin-ichi; Wakita, Hideaki; Bernstock, Joshua D et al. (2015) Hypophosphorylation of ribosomal protein S6 is a molecular mechanism underlying ischemic tolerance induced by either hibernation or preconditioning. J Neurochem 135:943-57
Lee, Yang-Ja; Mou, Yongshan; Klimanis, Dace et al. (2014) Global SUMOylation is a molecular mechanism underlying hypothermia-induced ischemic tolerance. Front Cell Neurosci 8:416
Castri, Paola; Lee, Yang-Ja; Ponzio, Todd et al. (2014) Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-kappaB-dependent signaling. Biochim Biophys Acta 1843:640-51

Showing the most recent 10 out of 26 publications